BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Rev 2021;47:100773. [PMID: 33213985 DOI: 10.1016/j.blre.2020.100773] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Shash HA, Khairy AM. Successful Treatment of Pediatric Acute Myeloid Leukemia Presenting with Hyperbilirubinemia Secondary to Myeloid Sarcoma: A Case Report. Children 2022;9:1699. [DOI: 10.3390/children9111699] [Reference Citation Analysis]
2 Souza PKD, Amorim RO, Sousa LS, Batista MD. Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions. Anais Brasileiros de Dermatologia 2022. [DOI: 10.1016/j.abd.2022.06.002] [Reference Citation Analysis]
3 Kanduła Z, Janowski M, Więckowska B, Paczkowska E, Lewandowski K. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome. J Cancer Res Clin Oncol 2022. [PMID: 36242602 DOI: 10.1007/s00432-022-04327-0] [Reference Citation Analysis]
4 Xing Z, Zhu X, Li Z, Wang H, Qian M, Zhai X. Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study. Front Oncol 2022;12:989366. [DOI: 10.3389/fonc.2022.989366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mahmoodi NO, Alavi SM, Yahyazadeh A. Formulation and therapeutic efficacy of PEG-liposomes of sorafenib for the production of NL-PEG-SOR FUM and NL-PEG-SOR TOS. Res Chem Intermed. [DOI: 10.1007/s11164-022-04777-8] [Reference Citation Analysis]
6 Gutiérrez-jimeno M, Panizo-morgado E, Calvo-imirizaldu M, Galán-gómez V, Escudero-lópez A, Patiño-garcía A. Case Report: The Value of Genomic Analysis in a Case of Megakaryoblastic Leukemia With Atypical Initial Manifestation. Front Pediatr 2022;10:875510. [DOI: 10.3389/fped.2022.875510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hisemová M, Ptáčník V. Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax. Onkologie 2022;16:155-158. [DOI: 10.36290/xon.2022.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhang X, Wang S, Wang F, Shen Q, Jia Y. Microtransplantation for myeloid sarcoma: Two case reports. Leukemia Research Reports 2022. [DOI: 10.1016/j.lrr.2022.100326] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, Salemi D, Agueli C, Palumbo GA, Santoro A, Di Raimondo F, Vetro C. Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers (Basel) 2022;14:2186. [PMID: 35565314 DOI: 10.3390/cancers14092186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert Opin Biol Ther 2022;:1-7. [PMID: 35350938 DOI: 10.1080/14712598.2022.2060735] [Reference Citation Analysis]
11 Lasocki A, Seymour J. Central nervous system manifestations of systemic haematological malignancies and key differentials. Clinical Radiology 2022. [DOI: 10.1016/j.crad.2022.01.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Arzoun H, Srinivasan M, Thangaraj SR, Thomas SS, Mohammed L. The Progression of Chronic Myeloid Leukemia to Myeloid Sarcoma: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.21077] [Reference Citation Analysis]
13 Mandhan N, Yassine F, Li K, Badar T. Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. Leuk Res Rep 2022;17:100286. [PMID: 34976720 DOI: 10.1016/j.lrr.2021.100286] [Reference Citation Analysis]
14 Mcquaid DC, Panse G, Wang W, Pinkus GS, Katz SG, Xu ML. Global Assessment of IRF8 as a Novel Cancer Biomarker. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia. Front Cell Dev Biol 2021;9:764698. [PMID: 34869355 DOI: 10.3389/fcell.2021.764698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Kelly M, Advani R, Schuster-bruce J, Crossley E, Lakhani R. Unilateral nasal obstruction: a rare presentation of acute myeloid leukaemia. Journal of Surgical Case Reports 2021;2021. [DOI: 10.1093/jscr/rjab581] [Reference Citation Analysis]
17 Halahleh K, Alhalaseh Y, Al-Rimawi D, Da'na W, Alrabi K, Kamal N, Muradi I, Abdel-Razeq H. Extramedullary acute myeloid leukemia (eAML): Retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes. Ann Med Surg (Lond) 2021;72:102894. [PMID: 34815855 DOI: 10.1016/j.amsu.2021.102894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Ann Hematol 2021. [PMID: 34686913 DOI: 10.1007/s00277-021-04702-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj AP, Howard MT, Hanson CA, Ketterling RP, Pardanani AD, Tefferi A. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol 2021. [PMID: 34346084 DOI: 10.1111/bjh.17742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Steinfeld PF, Knoop T, Trovik LH, Gjelberg HK, Haslerud TM, Reikvam H. Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. Clin Pract 2021;11:459-66. [PMID: 34449553 DOI: 10.3390/clinpract11030061] [Reference Citation Analysis]
21 Wang Y, Rui Y, Shen Y, Li J, Liu P, Lu Q, Fang Y. Myeloid Sarcoma Type of Acute Promyelocytic Leukemia With a Cryptic Insertion of RARA Into FIP1L1: The Clinical Utility of NGS and Bioinformatic Analyses. Front Oncol 2021;11:688203. [PMID: 34249738 DOI: 10.3389/fonc.2021.688203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Shatilova A, Girshova L, Zaytsev D, Budaeva I, Mirolyubova Y, Ryzhkova D, Grozov R, Bogdanov K, Nikulina T, Motorin D, Zammoeva D, Efremova S, Ivanov V, Petukhov A, Alekseeva Y, Zaritskey A. The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report. BMC Womens Health 2021;21:184. [PMID: 33933047 DOI: 10.1186/s12905-021-01328-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Nisticò D, Cortellazzo Wiel L, Berti I, Calligaris L, Rabusin M, Saccari A, Barbi E, Kiren V. Isolated Forehead Swelling. J Pediatr 2021;232:300-2. [PMID: 33444642 DOI: 10.1016/j.jpeds.2021.01.001] [Reference Citation Analysis]